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Abstract 
Objective: Cannabinoids are able to reduce tumor growth in xenograft models, but their therapeutic potential as 
anti‑cancer drugs in humans is unclear yet. In vitro studies of the effect of cannabinoids on cancer cells are often car‑
ried out in absence of serum or in low serum concentration (i.e. 0.5% serum), conditions that limit cellular growth and 
therefore can increase the response of cells to additional challenges such as the presence of cannabinoids. However, 
the tumor microenvironment can be teaming with growth factors. In this study we assessed the viability and prolif‑
eration of cancer cells treated with cannabidiol in presence of a serum concentration that commonly sustains cell 
growth (10% serum).
Results: The results show that cannabidiol exerts a markedly different effect on the viability of the human HT‑29 
cancer cell line when cultured in presence of 0.5% serum in comparison to 10% serum, displaying a cytotoxic effect 
only in the former situation. In presence of 10% serum, no inhibitory effect of cannabidiol on DNA replication of HT‑29 
cells was detected, and a weak inhibition was observed for other cancer cell lines. These results indicate that the effect 
of cannabidiol is cell context‑dependent being modulated by the presence of growth factors.
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Introduction
The cannabis plant has a therapeutic potential to treat a 
wide range of diseases, including cancer. Phytocannabi-
noids, are being tested in vitro and in vivo for the poten-
tial to fight different types of cancer. Cannabis extracts 
have recently been described to exert a cytotoxic effect 
on human cancer cell lines [13].
However, in  vitro cancer models, present limitations 
which reduce their predictive validity. One of these 
limitations is to reproduce the nutritional environment 
of the cells using cell culture media and growth factors 
[1]. Many in  vitro cancer studies use historical culture 
media with fetal calf serum (FCS). However, it is usual 
to eliminate or reduce FCS concentrations (i.e. FCS < 5%) 
from the media at the moment of drug exposure to avoid 
confounding effects of growth factors present in serum, 
as in many studies testing the cytotoxic properties of can-
nabinoids in cancer cells [12, 14, 15].
The deprivation of survival factors from the media can 
sensitize cells to a subsequent challenge. Pirkmajer and 
Chibalin [10] showed that the effects of serum starvation 
in cell cultures are unpredictable. According to Eastman 
[3], serum should be kept in cell cultures to avoid both 
false positive and negative results due to its effects on cell 
proliferation, stipulating the importance of replicating 
organic conditions to obtain clinically valid results.
In the present study, we analyzed the viability response 
of different cancer cell lines to cannabidiol (CBD) in pres-
ence of a standard concentration of serum (10%) in com-
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CBD was supplied by Schibano Pharma AG (Wald-
Schönengrund, Switzerland). McCoy’s 5A medium, 
Leibovitz’s L-15 medium (L-15) and RPMI 1640 and 
AlamarBlue® (AB) (Invitrogen) were bought from 
ThermoFisher Scientific (Barcelona, Spain). Paclitaxel, 
4′,6-diamidino-2-phenylindole (DAPI), dimethyl sulfox-
ide, L-glutamine, penicillin–streptomycin and FCS were 
bought from Sigma-Aldrich (Madrid, Spain). Cell Pro-
liferation Reagent WST-1 and 5-bromo-2′-deoxyuridine 
(BrdU) cell proliferation Elisa kit were bought from 
Roche, Sigma-Aldrich (Madrid, Spain). Paclitaxel was 
dissolved in dimethyl sulfoxide and CBD was dissolved in 
methanol at 80 mM and kept at −80 °C for a maximum 
of 2  months. When needed, Paclitaxel and CBD were 
diluted conveniently in the cell media at the indicated 
final concentrations. Cellular controls without CBD or 
Paclitaxel contained cell media without additives.
Cell culture
HT29 cells (ref. HTB-38) and SW480 cells (ref. CCL-
228) were obtained from American Type Culture Col-
lection. AGS cells were kindly provided by Miguel A. 
Pujana (Catalan Institute of Oncology, IDIBELL, Bar-
celona, Spain) and were originally obtained from Nuria 
Sala (Catalan Institute of Oncology, IDIBELL, Barcelona, 
Spain). Human colon cancer HT-29 cells and SW480 cells 
were maintained in McCoy’s 5A and L-15 media, respec-
tively. Human gastric cancer AGS cells, kindly provided 
by Francesca Mateo (Catalan Institute of Oncology, Bell-
vitge Institute for Biomedical Research, L’Hospitalet del 
Llobregat, Spain) were maintained in RPMI medium. All 
of the media was supplemented with 1% penicillin–strep-
tomycin and 2 nM L-Glutamine. 24 h before treatment, 
cells were plated in 96-well plates at 500–1000 cells/well. 
24  h later, wells in triplicates received CBD and Pacli-
taxel. All assays with SW480 and AGS cells included 10% 
FCS, while the assays using HT-29 cells included either 
10 or 0.5% FCS.
Cell viability and proliferation assays
For the viability and proliferation assay based on resa-
zurin and its redox-mediated reduction we used 10% AB 
and measured the fluorescence of the wells using a plate 
reader.
For the viability and proliferation assay based on cleav-
age of tetrazolium salts by mitochondrial dehydrogenase 
we used 10% WST-1.
For the proliferation based on the measurement of 
DNA synthesis we added BrdU to cells and detected 
its incorporation into DNA following manufacturer 
instructions.
To assess cell viability, DAPI was added to the cell sus-
pension 5  min before the analysis by flow cytometry. 
DAPI, emits higher fluorescence when bound to DNA. 
DAPI enters rapidly through altered cell membranes 
allowing the detection of damaged cells. The cell popula-
tion was selected by gating in a forward scatter vs. side 
scatter dot plot, excluding aggregates and cell debris. 
Samples were analyzed using a Gallios flow cytometer.
Statistical analysis
Data was analysed using IBM SPSS Statistics 23 and Real 
Statistics Using Excel.
We used Shapiro–Wilk test to assess data normality 
and non-parametrical independent samples Kruskal–
Wallis test to identify significant differences between 
each experimental condition. We used Dunn test as a 
post-hoc analysis to identify which groups show statisti-
cally significant differences.
Results
Viability and proliferation of HT‑29 cells with serum 
deprivation (0.5% FCS)
When human colon cancer HT-29 cells were incubated 
in media with 0.5% serum, adding CBD at 10 µM reduced 
cell viability as assessed via the resazurin method, which 
is based on evaluating mitochondrial reductive capac-
ity [11] (Fig.  1a). Interestingly, when CBD concentra-
tions were ≤ 4  µM, cell viability increased during the 
first 24  h. Differences between 2 or 4 and 10  µM were 
statistically significant (p = 0.006 and p = 0.013). At 48 h, 
the increasing viability with CBD ≤ 4  µM disappeared 
while the blocking effect of 10 µM CBD was more pro-
nounced (Fig.  1a). This suggests that CBD can induce 
mitochondrial stress, as reported by others [18]. Look-
ing at the morphology of cells, the treatment with 10 µM 
CBD led to changes in cell form, such as massive cellular 
detachment, cell rounding and presence of wrinkled cells 
characteristic of dead cells (Fig.  1b). In fact, analyzing 
the presence of dead cells using DAPI dye, we found an 
increased percentage in samples incubated with 10  µM 
CBD when compared to control cells (Fig. 1c). Thus, the 
loss of mitochondrial activity observed at CBD 10  µM 
correlated with cell death. Of note, at longer incubation 
times (i.e. 5 days) massive cellular death was also observ-
able at 4 µM CBD (data not shown). In summary, 10 µM 
CBD shows cytotoxic activity on HT-29 cells cultured in 
0.5% FCS.
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Viability and proliferation of HT‑29 cells in 10% FCS
Contrary to the drop in viability of cells in 0.5% FCS, 
CBD did not inhibit the viability of HT-29 cells even 
after 3 days in media containing 10% FCS (Fig. 2a, b). An 
apparent increase in HT-29 cell viability was observed at 
10  µM CBD, as assessed by AB or WST-1 (Fig.  2), sug-
gesting mitochondrial stress. We sought to find whether 
in these conditions CBD could show additive or syner-
gistic anti-proliferative effects with the therapeutic drug 
paclitaxel. Paclitaxel partially decreased the viability 
of HT-29 cells, according to AB measurement, but not 
WST-1. Thus, CBD at 10 µM does not grossly affect the 
viability of HT-29 cells after 3 days culture in presence of 
10% serum.
To ascertain whether CBD had any effect on prolif-
eration of HT-29 cells we measured the incorporation 
of BrdU into DNA. No changes in DNA synthesis were 
observed after 3  days of incubation of HT-29 cells with 
any concentration of CBD (Fig.  2c). Although paclitaxel 
in itself did inhibit DNA synthesis, CBD did not increase 
the effect of Paclitaxel (Fig. 2c). In summary, CBD up to 
10 µM do not decrease the viability nor the proliferation 
of HT-29 cells cultured in 10% FCS. None of these results 
showed statistically significant differences.
Viability and proliferation of SW480 and AGS cells
To know whether other cancer cell lines behaved simi-
larly to HT-29, showing little or no response to CBD 
when cultured in 10% FCS we used SW480, another 
colon cancer cell line and AGS, a gastric cancer cell line.
AGS cells did not show changes of viability by incuba-
tion with CBD up to 10 µM, though 2 nM Paclitaxel did 
decrease their viability (Fig.  3a). Higher Paclitaxel con-
centrations resulted in a severe decrease of AGS cells 
viability (data not shown) so we used 2 nm Paclitaxel to 
observe potential effects of CBD. The viability of SW480 
cells with CBD and 10% FCS showed a trend to decline 
(Fig. 3c). Surprisingly and contrary to HT-29 cells, 10 µM 
CBD did actually impair DNA replication in AGS and 
SW480 cells (Fig.  3b, d). In fact, the inhibition of DNA 
replication was additive to that produced by Paclitaxel. 
The assessment of DNA replication in SW480 cells 
Fig. 1 a HT‑29 cells were incubated with 0.5% FCS and different concentrations of CBD for 24 and 48 h. Cell viability was assessed by incubation 
with AB. The mean + SD of three assays are shown. b Morphology of HT‑29 cells incubated with or without 10 μM CBD for 24 h. Representative 
images are shown (bar, 20 µm). c HT‑29 cell viability according to DAPI staining (see the “Materials and methods” section). HT‑29 cells were 
incubated without (top) or with 10 μM CBD (bottom) for 24 h, stained with DAPI and immediately analyzed by flow cytometry. The cursor identifies 
DAPI‑positive cells (dead cells), showing a higher percentage in CBD‑treated cells. A representative experiment (c) is shown. *p < 0.05
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showed significant differences between the control sam-
ple and 10  µM CBD without paclitaxel (p = 0.021). Any 
other statistic analysis did not show significant results.
In summary, in presence of 10% FCS and during 3 days 
of culture, CBD does not affect the viability of HT-29, 
SW480 and AGS cells, though CBD at 10 µM does impair 
the proliferation of AGS and SW480 cells.
Discussion
In this study, we investigated the effects of CBD and 
its combination with Paclitaxel on the viability of three 
different cancer cells (HT-29, SW480 and AGS) under 
two different concentrations of serum, a standard 10% 
appropriate for cell growth (for HT-29, SW480 and 
AGS) and a restrictive one of 0.5% (for HT-29 only). For 
HT-29 cells, CBD only reduces cell viability under low 
FCS, with no effects on viability or DNA replication 
when cells were in 10% FCS. However, for SW480 and 
AGS, DNA replication was impaired under 10 µM CBD 
with 10% serum. Moreover, the inhibition of DNA rep-
lication in SW480 and AGS cells by CBD and Paclitaxel 
had an additive effect.
At low CBD concentrations HT-29 cells showed a 
trend towards increased cell viability, though the dif-
ferences were not significant. Different concentrations 
of CBD have previously been shown to have opposing 
effects on cells. Thus, 1 µM CBD induces proliferation 
of T leukemia cells, but at higher concentration kills 
the cells [9]. A low concentration, CBD increases mito-
chondrial  Ca2+ augmenting mitochondrial metabolism 
and cell growth, but at high concentration, it leads to 
Fig. 2 HT‑29 cells were incubated for 3 days with 10% FCS and 
different concentrations of CBD in absence or presence of 10 nM 
paclitaxel. a The viability was assessed by incubation with AB. 
The mean + SD are shown (n = 3). b The viability was assessed 
by incubation with WST‑1. The mean + SD are shown (n = 3). c 
Before harvesting, cells were incubated with BrdU for 2 h, which 
incorporated into DNA, and DNA synthesis was quantified. The 
mean + SD are indicated (n = 3)
Fig. 3 AGS cells and SW480 cells were incubated for 3 days with different concentrations of CBD in absence or presence of 2 nM Paclitaxel (AGS) or 
10 nM Paclitaxel (SW480). a, c Cell viability was assessed by incubation with AB. The mean + SD of three (AGS) and six (SW480) assays are shown. b, 
d Before harvesting, cells were incubated for 2 h with BrdU, which incorporated into DNA, and DNA synthesis was quantitated. The mean + SD of 
three assays (AGS) and 5 assays (SW480) are shown. *p < 0.05
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excessive mitochondrial  Ca2+, mitochondrial dysfunc-
tion and cell death [9].
Appropriate culturing conditions are essential for 
the survival and growth of cells. In many studies, cell 
culture conditions are not sufficiently detailed, which 
is essential for study replication. One possible solution 
to address the potential effect of serum could be using 
culture media without FCS, so the media does not 
need to be altered during drug exposition [17]. In any 
case, neither higher serum concentrations nor lower 
serum concentrations represent the proper microenvi-
ronment of a cancer cell in the human body, and both 
approaches could be valid to test the effects of a drug 
on cell lines. The tumor microenvironment is enriched 
with metabolites including lactate and adenosine [2, 4], 
which increases tumor growth and may modulate the 
therapeutic effect of a drug. In tumors that are highly 
glycolytic, increasing mitochondrial activity as exerted 
by CBD, may add metabolic stress to cells forcing them 
to decreased growth [5]. The effect of a drug on cells 
can be assessed effectively if the experimental condi-
tions of the treatment are the same as the growing con-
ditions before the treatment. Once growing conditions 
and treatment conditions differ from more than one 
variable (drug treatment) then the resulting effects can-
not be associated only to the treatment but to the com-
bination of variables.
Limitations
Our results did not show statistically significant differ-
ences with the exception of the assessment of viability 
of HT-29 cells under CBD treatment and the assess-
ment of DNA replication of SW480 under 10 µM CBD. 
The lack of statistically significant results could be due 
to the small sample size (n = 3 for most of the assays). 
Our study was also not able to replicate the strongly 
inhibitory effect of CBD shown in other studies where 
cannabinoids were tested against cancer cells cultured 
with 10% FCS. FCS contains many growth factors and 
nutrients, and differences in the FCS source could sub-
stantially modify the viability, proliferation and differ-
entiation of cultured cells. There are also other studies 
where cancer cells were cultured with 10% FCS and 
treated with CBD or other synthetic CBD-like mol-
ecules. The results of these studies showed that CBD 
(5–20 μg/mL) reduced the viability of cancer cells and 
also had effects on other survival variables [6–8, 16]. 
The cell lines used in these studies being different to the 
ones used in our study, could account for the different 
results observed.
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